CTAD 2025 1 - 4 December 2025

Semaglutide impacts proteomic signatures related to dementia risk in the SELECT cardiovascular outcomes trial

Authors :

Martí Jiménez-Mausbach¹; Jan Christian Refsgaard¹; Gabriel Martino¹; Teresa Leon Colombo¹; Betty Tijms²; Clare Paterson³

Affiliations

View Details Hide Details

{{ getPageNum(PDFPage) }}

Download poster (.pdf)

Keywords

Neurology

Congress poster

GLP-1 RA

Semaglutide (oral)

PHASE 2 (RCT)